
Bayer's Nubeqa approved in combo with androgen-blocking agent for prostate cancer
Bayer Korea said Monday that the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) has received approval from the Ministry of Food and Drug Safety (MFDS) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) as a two- …